Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Market Report: Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2013


Print article Print article
2013-12-19 12:40:42 - New Pharmaceuticals market report from Global Markets Direct: "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2013"

Global Markets Direct's, 'Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report

Details at
- www.fastmr.com/prod/755150_severe_acute_respiratory_syndrome_sar ..

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection.
* A review of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Novavax, Inc., CEL-SCI Corporation, NanoViricides, Inc., Protein Potential, LLC, AlphaVax, Inc., aRigen Pharmaceuticals, Inc., GeneCure LLC, Protein Sciences Corporation

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview
Therapeutics Development
An Overview of Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics under Development by Companies
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics under Investigation by Universities/Institutes
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics - Products under Development by Companies
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics Development
Novavax, Inc.
CEL-SCI Corporation
NanoViricides, Inc.
Protein Potential, LLC
AlphaVax, Inc.
aRigen Pharmaceuticals, Inc.
GeneCure LLC
Protein Sciences Corporation
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nelfinavir mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SARS Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CST-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-3252 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SARS Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxocarbazate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiocarbazate - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755150&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com